Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Valproate semisodium - AbbVie

Drug Profile

Valproate semisodium - AbbVie

Alternative Names: [14C]-Sodium Valproate; Depakote; Depakote ER; Divalproex; Divalproex sodium; Divalproex sodium DR 500mg tablets - Abbott Laboratories; Epival; Epival ER; LA40220

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; Sanofi
  • Class Antiepileptic drugs; Antimanics; Antimigraines; Pentanoic acids; Small molecules
  • Mechanism of Action Enzyme inhibitors; GABA agents; GABA modulators; Voltage-gated sodium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar disorders; Epilepsy; Migraine
  • Discontinued Dementia

Most Recent Events

  • 28 Dec 2021 No recent reports of development identified for phase-I development in Epilepsy(In volunteers) in United Kingdom (PO, Powder)
  • 14 Apr 2021 Discontinued - Phase-III for Dementia (In the elderly, In adults) in USA (PO)
  • 11 Apr 2019 Sanofi completes a phase I trial in Epilepsy (In volunteers) in United Kingdom (PO) (NCT03681158)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top